Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 63, Issue 1, 2009, Pages 115-120

  Han, Ji Youn ^a   Lim, Hyeong Seok ^a   Park, Yong Hoon ^a   Lee, Sung Young ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

Author keywords

ABCB1; ABCC2; ABCG2; Irinotecan; NSCLC; OATP1B1; UGT1A

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; ABC TRANSPORTER C2; ADENINE; BREAST CANCER RESISTANCE PROTEIN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A9; GUANINE; IRINOTECAN; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; THYMINE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; DIARRHEA; DISEASE SEVERITY; DRUG CYTOTOXICITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEUTROPENIA; PATIENT SELECTION; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; TUMOR GENE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DNA PRIMERS; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; SEX FACTORS; TREATMENT OUTCOME;

EID: 57649103563     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.12.003     Document Type: Article

References (31)

1. Van Cutsem E., Douillard J.Y., and Kohne C.H. Toxicity of irinotecan in patients with colorectal cancer. N Engl J Med 345 (2001) 1351-1352
2. Slatter J.G., Su P., Sams J.P., Schaaf L.J., and Wienkers L.C. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25 (1997) 1157-1164
3. Iyer L., King C.D., Whitington P.F., Green M.D., Roy S.K., Tephly T.R., et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101 (1998) 847-854
4. Haaz M.C., Rivory L., Riché C., Vernillet L., and Robert J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 58 (1998) 468-472
5. Santos A., Zanetta S., Cresteil T., Deroussent A., Pein F., Raymond E., et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6 (2000) 2012-2020
6. de Jong F.A., de Jonge M.J., Verweij J., and Mathijssen R.H. Role of pharmacogenetics in irinotecan therapy. Cancer Lett 234 (2006) 90-106
7. Innocenti F., Undevia S.D., Chen P.X., Das S., Ramirez J., Dolan M.E., et al. Pharmacogenetic analysis of interindividual irinotecan pharmacokinetic variability: evidence for functional variant of ABCC2. Proc Am Soc Clin Oncol 22 (2004) 2010
8. Iyer L., Ramírez J., Shepard D.R., Bingham C.M., Hossfeld D.K., Ratain M.J., et al. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother Pharmacol 49 (2002) 336-341
9. Schellens J.H., Maliepaard M., Scheper R.J., Scheffer G.L., Jonker J.W., Smit J.W., et al. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Ann NY Acad Sci 922 (2000) 188-194
10. Nozawa T., Minami H., Sugiura S., Tsuji A., and Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33 (2005) 434-439
11. Han J.Y., Lim H.S., Shin E.S., Yoo Y.K., Park Y.H., Lee J.E., et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24 (2006) 2237-2244
12. Han J.Y., Lim H.S., Yoo Y.K., Shin E.S., Park Y.H., Lee S.Y., et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110 (2007) 138-147
13. Han J.Y., Lim H.S., Shin E.S., Yoo Y.K., Park Y.H., Lee J.E., et al. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer. Lung Cancer 59 (2008) 69-75
14. Han J.Y., Lim H.S., Lee D.H., Ju S.Y., Lee S.Y., Kim H.Y., et al. Randomized phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced non-small cell lung carcinoma. Cancer 106 (2006) 873-880
15. Lee J.S., Lee D.H., Han J.Y., Lee J.J., Park S.H., Song J.E., et al. Randomized phase II cross-over sequential chemotherapy trial of irinotecan/cisplatin vs. gemcitabine/vinorelbine in chemo-naïve patients with stage IIIb/IV non-small cell lung cancer. Proc Am Soc Clin Oncol 24 (2006) 7134
16. Mathijssen R.H., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7 (2001) 2182-2194
17. Vanhoefer U., Harstrick A., Achterrath W., Cao S., Seeber S., and Rustum Y.M. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 19 (2001) 1501-1518
18. Gupta E., Lestingi T.M., Mick R., et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54 (1994) 3723-3725
19. Gupta E., Mick R., Ramirez J., Wang X., Lestingi T.M., Vokes E.E., et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase I inhibitor irinotecan in cancer patients. J Clin Oncol 15 (1997) 1502-1510
20. Canal P., Gay C., Dezeuze A., Douillard J.Y., Bugat R., Brunet R., et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14 (1996) 2688-2695
21. de Jonge M.J., Sparreboom A., Planting A.S., van der Burg M.E., de Boer-Dennert M.M., ter Steeg J., et al. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors. J Clin Oncol 18 (2000) 187-194
22. de Jonge M.J., Verweij J., de Bruijn P., Brouwer E., Mathijssen R.H., van Alphen R.J., et al. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin. J Clin Oncol 18 (2000) 195-203
23. Strassburg C.P., Nguyen N., Manns M.P., and Tukey R.H. UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology 116 (1999) 149-160
24. Horikawa M., Kato Y., Tyson C.A., and Sugiyama Y. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet 17 (2002) 23-33
25. Ratain M.J. Insights into the pharmacokinetics and pharmacodynamics of irinotecan. Clin Cancer Res 6 (2000) 3393-3394
26. de Jong F.A., Scott-Horton T.J., Kroetz D.L., McLeod H.L., Friberg L.E., Mathijssen R.H., et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 81 (2007) 42-49
27. Lockhart A.C., Tirona R.G., and Kim R.B. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2 (2003) 685-698
28. Lepper E.R., Nooter K., Verweij J., Acharya M.R., Figg W.D., and Sparreboom A. Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics 6 (2005) 115-118
29. Cusatis G., Gregorc V., Li J., Spreafico A., Ingersoll R.G., Verweij J., et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98 (2006) 1739-1742
30. Mizuarai S., Aozasa N., and Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109 (2004) 238-246
31. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391